Today: 8 June 2026
Browse Category

NASDAQ:ZEAL 6 March 2026 - 8 June 2026

Zealand Pharma Shares Sink 25% After Trial Results

Zealand Pharma Shares Sink 25% After Trial Results

Zealand Pharma shares plunged 26.02% to 241.40 Danish crowns after investors focused on a 19% discontinuation rate for Boehringer’s obesity drug survodutide in the SYNCHRONIZE-1 trial, far higher than the 2.9% for placebo, despite strong fat-loss data, making the stock the worst performer on Europe’s STOXX 600 in early trade.
8 June 2026
·
Zealand Pharma A/S shares plunge as petrelintide results trail Lilly in obesity race

Zealand Pharma A/S shares plunge as petrelintide results trail Lilly in obesity race

Zealand Pharma shares fell 32.53% to 249.10 Danish crowns by mid-morning Friday after new data for its obesity drug petrelintide disappointed investors, erasing about 8.3 billion crowns ($1.3 billion) in market value. A Phase 2 study showed up to 10.7% weight loss over 42 weeks, well below results seen with Eli Lilly’s rival drug. No vomiting or discontinuations due to gastrointestinal side effects were reported.
6 March 2026
·

Stock Market Today

  • SCHD ETF Seen as Defensive Buy Amid Potential Market Correction
    June 8, 2026, 5:20 AM EDT. The S&P 500's Shiller CAPE ratio reached 42, a signal last seen before the 2000 tech collapse, raising concerns about a potential stock market correction. Factors such as high inflation, slowing GDP growth, and tariff threats increase downside risks. The Schwab U.S. Dividend Equity ETF (SCHD) is highlighted as a smart defensive buy, focusing on high-quality, dividend-paying stocks with strong balance sheets. SCHD offers a 3.3% dividend yield and outperformed the market in 2022, declining only 3% versus the S&P 500's 18% drop. This ETF's portfolio of approximately 100 durable companies could help investors mitigate downside risk while generating income during volatile market conditions.

Latest articles

Zealand Pharma Shares Sink 25% After Trial Results

Zealand Pharma Shares Sink 25% After Trial Results

8 June 2026
Zealand Pharma shares plunged 26.02% to 241.40 Danish crowns after investors focused on a 19% discontinuation rate for Boehringer’s obesity drug survodutide in the SYNCHRONIZE-1 trial, far higher than the 2.9% for placebo, despite strong fat-loss data, making the stock the worst performer on Europe’s STOXX 600 in early trade.
Intel’s AI Stock Run Stalls; Monday Premarket Move Fails to Settle It

Intel’s AI Stock Run Stalls; Monday Premarket Move Fails to Settle It

8 June 2026
Intel shares rose 1.6% to $100.74 in pre-market trading Monday, partly rebounding from Friday’s 7.9% drop that followed a strong U.S. jobs report and a tech selloff; investors now face a key test as Intel’s AI partnerships with Foxconn and others lack visible orders or financial details, while options pricing signals potential for another 9% stock move this week amid inflation data and shifting rate expectations.
Nvidia’s $5 Trillion Valuation Gets Put to the Test Monday

Nvidia’s $5 Trillion Valuation Gets Put to the Test Monday

8 June 2026
Nvidia shares hovered near Friday’s 6% drop and $300 billion market cap loss despite new South Korean AI deals, as chip stocks reeled from fears of higher U.S. rates and regulatory risks; investors await Monday’s open to see if fresh partnerships can offset sector volatility and valuation pressure.
Nokia drops after fast AI rally, traders stay focused

Nokia rally stalls as traders sell tech stocks after AI push

8 June 2026
Nokia shares plunged 2.98% in Helsinki to 12.690 euros, extending losses as investors dumped AI-linked tech stocks amid rising oil prices and rate fears; U.S. ADRs dropped 13.48% Friday, while no new operating update was given and Nokia issued 500 million euros in new debt, with the next key earnings test set for July 23.
SpaceX Sets IPO at $135, Retail Buzz Ahead of SPCX Nasdaq Debut

SpaceX Sets IPO at $135, Retail Buzz Ahead of SPCX Nasdaq Debut

8 June 2026
SpaceX’s $75 billion IPO launches June 12 at $135 a share, with retail demand already double the shares on offer and 30% of the deal earmarked for individuals, but 2025 losses of $4.94 billion and a $1.75 trillion target valuation raise questions about post-IPO pricing as index entry and profitability remain uncertain.
Go toTop